Your browser doesn't support javascript.
loading
Mitochondrial Priming by CD28.
Klein Geltink, Ramon I; O'Sullivan, David; Corrado, Mauro; Bremser, Anna; Buck, Michael D; Buescher, Joerg M; Firat, Elke; Zhu, Xuekai; Niedermann, Gabriele; Caputa, George; Kelly, Beth; Warthorst, Ursula; Rensing-Ehl, Anne; Kyle, Ryan L; Vandersarren, Lana; Curtis, Jonathan D; Patterson, Annette E; Lawless, Simon; Grzes, Katarzyna; Qiu, Jing; Sanin, David E; Kretz, Oliver; Huber, Tobias B; Janssens, Sophie; Lambrecht, Bart N; Rambold, Angelika S; Pearce, Edward J; Pearce, Erika L.
Afiliação
  • Klein Geltink RI; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • O'Sullivan D; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Corrado M; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Bremser A; Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, 79106 Freiburg, Germany; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Buck MD; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Buescher JM; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Firat E; Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • Zhu X; Shanghai Institute for Advanced Immunochemical Studies (SIAIS), Shanghai Tech University, 201210 Shanghai, People's Republic of China.
  • Niedermann G; Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Caputa G; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Kelly B; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Warthorst U; Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Rensing-Ehl A; Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Kyle RL; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Vandersarren L; Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, 9052 Ghent, Belgium; Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium.
  • Curtis JD; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Patterson AE; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Lawless S; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Grzes K; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Qiu J; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Sanin DE; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Kretz O; Department of Neuroanatomy, University of Freiburg, 79104 Freiburg, Germany; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Huber TB; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Department of Medicine IV, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; BIOSS Center for Biological Signaling Studies and Center for Syste
  • Janssens S; Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, 9052 Ghent, Belgium; Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium.
  • Lambrecht BN; Laboratory of Immunoregulation and Mucosal Immunology, VIB Center for Inflammation Research, 9052 Ghent, Belgium; Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium.
  • Rambold AS; Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, 79106 Freiburg, Germany; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.
  • Pearce EJ; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany; Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
  • Pearce EL; Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany. Electronic address: pearce@ie-freiburg.mpg.de.
Cell ; 171(2): 385-397.e11, 2017 Oct 05.
Article em En | MEDLINE | ID: mdl-28919076
ABSTRACT
T cell receptor (TCR) signaling without CD28 can elicit primary effector T cells, but memorycells generated during this process are anergic, failing to respond to secondary antigen exposure. We show that, upon T cell activation, CD28 transiently promotes expression of carnitine palmitoyltransferase 1a (Cpt1a), an enzyme that facilitates mitochondrial fatty acid oxidation (FAO), before the first cell division, coinciding with mitochondrial elongation and enhanced spare respiratory capacity (SRC). microRNA-33 (miR33), a target of thioredoxin-interacting protein (TXNIP), attenuates Cpt1a expression in the absence of CD28, resulting in cells that thereafter are metabolically compromised during reactivation or periods of increased bioenergetic demand. Early CD28-dependent mitochondrial engagement is needed for T cells to remodel cristae, develop SRC, and rapidly produce cytokines upon restimulation-cardinal features of protective memorycells. Our data show that initial CD28 signals during T cell activation prime mitochondria with latent metabolic capacity that is essential for futurecell responses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ativação Linfocitária / Linfócitos T / Antígenos CD28 / Mitocôndrias Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ativação Linfocitária / Linfócitos T / Antígenos CD28 / Mitocôndrias Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha